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Abstract 
 
Affective-related disorders, including depression are constantly rising, complicating people’s personal life style 
increasing disqualification and hospital care. Because of the high intensity of urbanization, our lifestyle and food 
altered dramatically in the last twenty years. These food modifications have been associated to scores of depression 
and other affective-related disorders in urbanized countries with high economic levels. Nutrients imbalance is 
considered as one of the critical causes enabling to the pathophysiological mechanisms for the development of 
psychiatric disorders. Application of additional nutritional interventions for treatment of mood deteriorations can be 
beneficial for both the prophylaxis and therapy of affective-related disorders. This paper will review recent research 
on the relation of Vitamin D levels and the epidemiology of depression in women. 
In this paper we will provide an overview of the results of a variety of different studies taking on board research which 
both suggests and refutes an association. Based on these findings we will propose important directions for future 
research in relation to this topic.  
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1. Introduction  
 
The ever-popular Vitamin D (VD) is commonly known as the «sunshine vitamin» [1] and (like sunshine) is implicated 
to positively alter mood. VD itself is known as a secosteroid hormone, recognized as a neuroprotective factor which 
plays a role in brain development [2,3]. VD is involved in a range of important physiological processes, such as in 
promoting cell growth and differentiation, facilitating immunomodulation regulation, and being involved in 
neurotransmission, and anti-inflammatory effects. On the other hand, low concentrations or deficiency of VD have 
been associated with various mental and neuropsychiatric disorders, consisting of psychotic and mood disorders, 
autism, and cognitive decline [2,3]. No doubt, depression plays a very important role in women’s disease-related 
disabilities. The current paper will review and summarize recent research on the relation of VD levels and the 
epidemiology of depression in women. In this paper, we will outline relevant studies about the relationship between 
VD and depression in women in an attempt to provide useful recommendations in terms of future scientific questions 
that need to be addressed in this research area.  
 
2. Vitamin D and lifestyle 
 
Vegetables, herbs and fruits can contribute to a person’s health in terms of the levels of VD2, while meat and fish 
(especially fatty fish) can contribute to VD3. This means that VD levels are influenced by environment and lifestyle. 
However, except for fatty fish, relatively few foods naturally contain large amounts of VD [4].  A recent meta-analysis 
of 31 studies (with 79366 individuals) showed that some genetic factors might also modulate VD levels [5]. The 
findings of this meta-analysis were also suggestive of a relatively small heritability rate for VD levels, but overall 
indicated that modifiable environmental factors are the main determinants of VD levels.  
Ultraviolet sunlight synthesis of VD depends on the season, latitude, and amount of skin exposure [6]. Levels of VD 
vary seasonally, with deficiency more common in winter and at higher latitudes, reflecting ambient levels of sunlight 
[6], as well as in urban settings, owing to lifestyle choice and lower sunlight exposure [7]. Due to difficulties of darker 
skin to absorb sunlight, Black and Asian populations are more likely to be affected by lower levels of VD and related 
negative consequences on health [8]. In most parts of the world, during sunny months optimal levels of VD 
(approximately 1.000 IU per day) can be achieved by minimal (5 to 15 minutes depending on the level of sun) sun 
exposure of face, arms, and hands without sunscreen [13]. 
The liver transports consumed VD2 and VD3 with the use of chylomicrons. Plasma which then binds to proteins in 
turn caries the VD3 which originates from sunlight exposure [9]. VD is synthesized predominantly endogenously 
(approx. to 90% of the total VD in human body). In the skin, the ultraviolet light transforms 7 -dehydroxycholesterol 
(provitamin D) to pre-vitamin D, which under the influence of body temperature spontaneously isomerizes to 
cholecalciferol (VD3). Approximately 10% of total body VD is taken orally (ergocalciferol and cholecalciferol). VD 
is transported via VD-binding protein to the liver, where it is hydroxylated to 25-hydroxyVD [9,10]. The next step in 
VD activation is hydroxylation of 25VD by the enzyme 1α – hydroxylase (CYP27B1) to 1,25-dihydroxyvitamin D 
(1,25VD), which is the active VD metabolite. This process occurs predominantly in the renal tubules. In addition, 
non-renal CYP27B1 was detected in skin (basal keratinocytes, hair follicles), lymph nodes (granulomata), colon 
(epithelial cells and parasympathetic ganglia), pancreas (islets), adrenal medulla, brain (cerebellum and cerebral 
cortex), prostate epithelial cells and placenta (decidual and trophoblastic cells), indicating the wider significance of 
the VD metabolites [10]. Finally, 1,25VD is inactivated by the enzyme 24-hydroxylaze. 
1,25VD exerts its effect via the VD receptor (VDR), which is detected in all human organs [10-12]. 1,25VD binds to 
VDR, the complex forms a heterodimer with the receptor for retinoid X (RXR) within the nucleus. The 1,25VD-VDR-
RXR complex binds to VD reacting elements, modulating gene expression [10,11].  
Dietary intake of VD rich foods is also important for maintaining healthy 25(OH)VD levels, especially when direct 
sun-exposure is low. VD status is being evaluated via the serum level of 25(OH)VD – the metabolite formed in the 
first hydroxylation in the liver, due to its longer half-life (approximately 3 weeks), compared to the active metabolite 
1,25(OH)VD (4 – 6 hours) [15]. There is a consensus among experts that we should revise the recommendations 
for VD intake of 200-600 IU per day which is currently in place, as these cannot adequately prevent VD 
insufficiency [14, 15]. A healthier recommendation for VD related food intake for individuals with low levels of 
sunlight exposure would range from 800 to 1000 IU per day. This would subsequently also affect 25(OH) VD levels 
to be more in the preferred range (30–40 ng/ml) and affect VD related health consequences [15].  
 
3. Women and depression: pathophysiology and epidemiology descriptive  
 
Depression is a condition characterized by at least a 2 weeks period of a variety of symptoms, which include; low and 
depressed moods, feeling of worthlessness and/or hopelessness, loss of pleasure and/or interest in daily activities, 
decreased energy levels, loss of appetite, disturbance of sleep, and changes in psychomotor function, and s uicidal 
ideation and/or action [16,17]. Nowadays, approximately 840 million people worldwide are affected by depression 
with females being affected more commonly than males (at a ratio of roughly 2:1) [16]. 
 
 3.1. The pathophysiology of depression  
 
Genetic and epigenetic factors have commonly been named as playing a potential role in depression. Belmaker and 
Agam [17], however, also argued for two other predominantly pathophysiological contributors of depress ion, which 
we will outline below. First, according to the «monoamine deficiency hypothesis», with respect to the brain depression 
can be related to the functioning and amount of monoamine neurotransmitters.  Traditionally, selective serotonin 
reuptake inhibitors (SSRIs)/selective norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, and 
tricyclic antidepressants are commonly prescribed for treatment of affective-related disorders. It is generally accepted 
that these psychotropic drugs can reduce levels of biogenic monoamines in the structures of the brain that are closely 
involved in the pathophysiology of mood disorders [17]. While some research has found that levels of serotonin and 
norepinephrine are reduced among those people suffering from depression, research does also suggest that 
impairments in the functioning of monoamine plays a role in depression  [17].  It has for example been demonstrated 
that depression can be produced in individuals with a history of the disorder when levels of neurotransmitter substrates 
are intentionally depleted [18] yet, the depletion of these neurotransmitter has not been found to effect healthy 
individuals. This can be interpreted as monoamine malfunctioning playing an important role in people’s predisposition 
to depression. 
The second hypothesis suggest that the onset of depression can partly be explained by the pathophysiological impact 
of stress [17]. It is well-known that stress factors activate the corticotropin-releasing hormone (CRH) release rein the 
hypothalamus, which produces secretion of the adrenocorticotropic hormone (ACTH) by the pituitary gland, which 
than induces cortisol release from the adrenal glands [18,19]. This suggest that reduced functioning of the 
hypothalamic-pituitary-adrenal (HPA) axis may directly contribute to mood disorders such as depression and anxiety. 
However, support for this hypothesis is mixed, as clinical studies among individuals with depression have not 
consistently found that cortisol levels or the function of the HPA axis in depressed individuals are different than in 
non-depressed counterparts [18,19]. Supporting this hypothesis, it was, however found that some depressed 
individuals had chronically elevated cortisol levels, increased CRH levels in their cerebrospinal fluid, and impaired 
negative feedback [19]. Moreover, recent research [20], also found that the hippocampus of depressed individuals was 
significantly smaller than in non-depressed individuals and found lower levels of neurogenesis in their hippocampus 
as a result to stress. Moreover, other evidence for this hypothesis comes from studying the working of antidepressants, 
as these stimulate monoamines which affect stress related activity of the HPA axis [20].  
 
3.2. Epidemiology  
 
The estimated total population prevalence of major depression is ranging between 6% and 17% [26]. However, 
research on the psychiatrics epidemiology of depression has extensively found that women more commonly suffer 
from depression than men and that women have higher risk to develop depression than men. This trend is already 
present among teenagers  [21-24] and mood disorders in this group are estimated to be one and a half to three times 
as high among women when compared to men [25]. Mood disorder related sex differences continue during 
adolescence, with girls experiencing elevated depression scores compared to boys [28-31]. A small numbers of 
epidemiological studies on minor depression [35] or brief recurrent depression [36] have found more depression 
prevalence among women than men. Moreover, in survey research among young individuals it was found that this 
gender divergences starts  at the age of  11 to14 years old [37], and that the likelihood of girls to develop depression 
over boys is clear by the age of 12 years  and follows through the lifespan. When studying minor depression and 
dysthymia many epidemiological studies have also found similar results, with a female to male prevalence ratio around 
2 to 1 [27]. Fortunately, depression symptoms are still reduced for early childhood (<1%) and research fails to 
demonstrate statistically differences for depression development in boys and girls during this stage [32-34]. 
The above findings may indicate that sex gonadal hormones have a role in the heightened predominance of depression 
scores among women. These hormones such as progesterone and estrogen have been reported to have a key role in 
depression among women [38]. Moreover, a nuanced interplay between the HPA axis and sex specific hormones may 
also play a very significant role in the onset of depression [38]. Clinical studies reported that affective-related disorders 
in women are more frequently connected with other pathophysiological alterations in their organism, such as 
modifications of sex hormones levels for menopause [39], taking birth control, or undergoing hormonal replacement 
therapy [40]. 
It is well-known that gonadal steroid receptors are nuclear receptors which act as transcription factors and can thereby 
induce long-lasting effects on the brain functions modulating gene expression [38]. Moreover, gonadal hormones have 
both organizational influence on organisms (creating permanent modifications during critical periods of development) 
and ameliorating influence on organisms (facilitating transient influence on organism). Endocrine imbalance or 
abnormal functioning of steroids receptors can therefore significantly change monoamines balance in the brain, 
especially serotonin and noradrenalin levels [41]. Estrogens imbalance significantly contributes to the vulnerability of 
women to become depressed and may also contribute  to physiological alterations in the effectiveness of 
pharmacological therapy.  
It is well-established that gender differences in depression occur for the first time at adolescence with great scores in 
adulthood [42]. That is why adult women have higher rates of depression compared to other populations [42]. In this 
age group, depression levels are similar to other stages of life, but the specific mechanism of affective-related disorders 
is not completely understood [43]. Nevertheless, the evidence clearly indicates that genes interact with the 
environment [43,44] and a particularly provocative impact of hormonal balance. 
Another high-risk period for developing a new depression episode in women is during pregnancy or after birth of a 
child and this is especially the case for women who have had mental health problems or depressive symptoms before 
[45]. It has been found that 10 to 16 % of pregnant women will suffer from depression [46-48]. Moreover, women 
with bipolar disorder during pregnancy are estimated to have moderate rate relapse between 30% and 50% during 
the postpartum period. 
These findings are in line with general reports that the risk of the development of mood disorders is enhanced with a 
past medical report of affective-related disorders [49-50].  It has however also been found that a third of depressed 
pregnant women have never had major depression before [51]. Other risk factors for antenatal depression include; 
marital issues, a lack of or inadequate social support, recent negative life events, low socio-economic status, and 
unplanned pregnancies [50,52]. 
Adolescence, pregnancy, parturition, and reproductive senescence are all  well-established states in women which  are 
characterized by a profound hormonal shift. . The earlier studies postulated that depression which is associated with 
estrogen deficiency in menopause related to a number of physiological factors, among which loss of fertility [53,54]. 
These factors can be the biological drivers that increase susceptibility for depressive disorders. Perimenopause is also 
characterized by estrogen deficits and is accompanied by affective-related disorders [42,55]. It was found that women 
without clinical manifestations of depressive episodes before the menopause, but with medical report of early life 
adversity, have a higher risk for the development of depressive-like disorders during the menopause in contrast to 
women without such a  history earlier in life [56]. The main predictors for depression in the menopausal period in 
women are; postpartum depression, miscarriages, or no live births [53]. Moreover, there are some association between 
vaginal dryness and/or hot flashes and the symptoms of perimenopausal depression in women [57,58]. Furthermore, 
appearance of depression in menopausal women can be more declared than earlier in life [59]. These results indicate 
that deteriorations of the normal cyclicity of female hormones may intensify the risk for development of depression 
in women at the menopausal transition. These findings are consistent with the hypothesis that female hormones 
imbalance can drive postpartum depression [60- 61]. Interestingly, a history of major depressive episodes in women 
is very often linked to an earlier lack in functioning of the ovaries [62], indicating that the relationship between female 
steroids and mood disorders may be synchronous. The depressive symptoms levels at post-menopause state are 
much more comparable to those of men [63], indicating that the negative effects of female gonadal hormones have 
weakened. Neuroactive steroids, nevertheless, keep their biological activity in the central nervous system even after 
the menopause. Additionally, the general organizational effects of female hormones in the brain are presented during 
all life in women.  Thus, the total endocrine medical record of a woman, especially following menopause, may provide 
her more or less vulnerable to arising episodes of depression [64].  
 
4. Vitamin D and women depression: is there a relationship?  
 
Only few studies or reviews demonstrated that VD insufficiency is corresponded to mood disorders in young females 
with good health, even despite women's high rates of mood disorders and increasing evidence to show that VD 
deficiency is associated with depression [65]. Moreover, a long-term clinical work recently showed that the cumulative 
rate of depression was 63.4% for women vs. 34.7% for men [66]. So, depression puts a huge health burden on women 
in specific. Moreover, even without a VD deficiency, it has been documented in many studies that individuals with a 
normal to high levels of VD develop depression [67-77].  
There is a growing scientific opinion that links VD deficiency to the pathophysiology of depression [78 -81]. Four 
lines of evidence proposed that the biological mechanisms play  an important role in this: first – there are receptors of 
VD distributed in various areas of the brain (limbic system, cerebellum, and cortex) which control behaviors and are 
involved in emotional processing and affective-related disorders [82-85], second – there are lower levels of VD in 
depressed people compared to controls [67,78,80,86], third - VD regulates the synthesis of serotonin via the 
modulation of the tryptophan hydroxylase 2 gene expression  [87], fourth – there is an important modulatory role for 
VD in the regulation of immuno-inflammatory pathways that has proven to be relevant to the pathophysiology of 
depression by activating the stress response [88-94].  
The above-mentioned evidence has spawned a series of trials (with mixed results) that have tried to answer the 
question whether VD supplementation among depressed patients might improve their depression scores. Thus far, a 
few meta-analyses have included studies assessing the effect of VD on depressive symptom scores in individuals 
without a clinical diagnosis of major depression [95-99]. Further, as the authors of these studies point out, many of 
the included patients had very low depression scores to begin with, which may be the reason f or the marginal effects 
noted. However, the observational nature of the included studies don’t give any clear conclusion on a typical link 
between VD and depression. Therefore, there is little longitudinal data on the relationship between VD and depression . 
Thus far, meta-analyses indicate that VD treatment failed to markedly reduce manifestation of depression [98,100]. 
Recently, a large-scale population-based study, included 3.251 adults of over 55 years old, examining long-term 
associations between serum VD levels and depression identified a cross-association between low VD and depression, 
but did not reveal any evidence of a longitudinal relationship [101]. However,  if VD is a risk factor for depression, 
Commented [ATvd1]: This sentence looks out of place 
we would expect VD concentrations to have a longitudinal association with depression and depressive symptoms, 
which was not found in this study [101]. Although this is in contradiction with the findings of two other longitudinal 
studies [102,103] and with studies of Vellekatt [103], which revealed a relationship between suboptimal VD  
concentrations and the presumed appearance of mood disorders.  
A meta-analysis explored randomized controlled trials  (RCTs) in which VD supplementation was used as a treatment 
for depression and identified six RCTs with 1203 participants (72% women), 71 of whom were with current depression 
(5 trials included patients at risk of depression and 1 trial included patients with depression). There was no significant 
effect of VD supplementation on depression scores [104,105].. From this systematic review and the aforementioned 
systematic review of Anglin [70] are corroborated the conclusion of previous narrative reviews, indicating that no 
clear causal relationship between suboptimal VD levels and depression was identified. Nevertheless, the evidence on 
the relationship between VD and depression poses the problem that  numerous preclinical and clinical 
studies involve older populations or populations undergoing drug treatmentss meaning that more research will be 
needed on this topic [106-108].  
 
5. Application of Vitamin D as preventive and curative agent in women with different health conditions for 
treatment of depression 
 
Only one small, randomized, double-blind trial of VD3 augmentation of a specific antidepressant in depressive disorder 
has occurred. This involved, a clinical study [109], consisting of fifty female participants with type 2 diabetes mellitus 
(T2DM) and markedly depressive symptoms, all of whom were participating into the “Sunshine Study,” as part of 
which VD treatment for 7 days (ergocalciferol, 50.000 IU) was applied on a daily basis for a 6 months period. 92% of 
the women that were examined in this study demonstrated depressive and anxiety symptoms (PHQ-9, State-Trait 
Anxiety), and worse health parameters (SF-12). A profound reduction of depression (CES-D and PHQ-9) and anxiety 
scores, as well a high level of mental health status (SF-12) were registered in women treated with VD. The deficit in 
depressive parameters remained marked (CES-D) when additionally testing for probits (baseline depression (PHQ-9), 
baseline VD, body mass index, race, and season of enrollment). Moreover, women who did not apply 
antidepressants/anxiolytics had a more significant therapeutic response to VD treatment. Im other words, the  
conclusion of this randomized trial indicates that VD treatment for correction of physiological and psychological 
health in T2DM women is beneficial.  
Another study reports that 11% of pregnant women showed strong VD deficiency, and 40.3% of them had a 
moderate VD deficiency. During pregnancy EPDS scores and 25(OH)D3 levels were found to be inversely correlated 
with higher depressive symptoms relating to lower 25(OH)D3 levels. A significant negative correlation was also found 
for VD levels and depressive symptoms at three postpartum times. Moreover, cross-sectional study showed that 
elevated VD food intake may be associated with lower levels of depressive symptoms during pregnancy. Moreover, 
the enhanced serum VD levels were significantly correlated with decreased levels of depressive symptoms during 
pregnancy [111]. 
In another study, 47 women with problems with their levels of VD [112] were selected. 16 women with VD deficiency 
were then submitted to VD treatment (4.000 IU daily, per os) for 6 months. In turn, 31 women with VD insufficiency 
were equally divided into  2 groups: one group of  17 women who were  treated with VD preparations (2.000 IU daily, 
per os) or another group of 14 women who were not treated with  any VD therapy. All women from this study filler 
in several  questionnaires estimating depressive symptoms (BDI-II) and female sexual functioning (FSFI). The total 
FSFI score and scores on several of the sub-scales (orgasm, sexual desire, and satisfaction) were decreased for the 
treatment compared to the control group. However, the overall BDI-II score statistically increased in women 
with VD deficiency compared to women with VD insufficiency. VD enhanced sexual parameters (overall FSFI score, 
desire, orgasm, and sexual satisfaction) in both groups of patients with VD deficiency and VD insufficiency, and 
diminished the overall BDI-II score in women with VD deficiency. These findings suggest that VD application 
contributes to mood and female sexual functioning in women with low VD blood levels. 
In a clinicalm double blind, randomized controlled trial sy 80 perimenopausal women who had a score ≥ 13 on the 
Edinburgh Postnatal Depression Scale and ≥ 20 on the Fatigue Identification Form, respectively, were randomly 
divided to the experimental or control subgroups over a 4 to 10 months after giving birth [113]. One group of women 
form this study  was treated by VD3 1000 IU on a daily basis over a period of six months, whereas the women in the 
control group received a placebo drug for the same period of time.  VD treatment reduced depression and fatigue 
scores in depressed women. Based on these results the authors proposed that VD application should be suggested as 
a standard treatment for women who have a high trigger factors for depression in the postpartum period after birth. 
Other randomized trials [114] have shown benefits with VD supplementation in seasonal affective disorder (100.000 
IU daily, per os) patients hospitalized in a general hospital receiving 20.000 IU VD3 twice a week compared with 
placebo (participants were neither VD deficient nor clinically depressed) [115]. Nevertheless, a randomized clinical 
study in which  VD3 (800 IU, per os, daily) was given to  women aged 70 or over did not identify any significant 
improvement in mental health outcomes with supplementation, although the study was limited by a low level of 
depression in the study sample and the moderately low dose of VD3 [116]. 
On the other hand, numerous studies might validate several of the above conclusion. More specific, some of the above 
studies are limited by being underpowered, due to small sample sizes. In addition, most conclusions have been based 
on heterogeneous study populations which has resulted in inconsistent results, which at best provide a slight signal of 
a beneficial effect of VD on mood [116]. In sum findings till data are far from conclusive. The summarized data from 
several studies is presented in Table 1.  
 
6. Discussion and Conclusion  
 
Their appears food evidence that early-life lack of VD may be as physiological trigger for depression development at 
a later period in  life. It may be that VD at non-optimal levels is no longer neuroprotective, perhaps because of the 
loss of its antioxidant or anti-inflammatory effects, making it more vulnerable to emerging neuropsychiatric diseases 
such as affective-related disorders. VD deficiency has been associated with poorer mental health, depression and 
psychotic disorders, as well as chronic physical problems. However, the factual basis that VD is a potential cause 
rather than the consequence of                                                                                                                                                                                                             
Table 1 
 Effects of Vitamin D treatment on affective-related state in women 
 
Women’s health status  
Dose/duration of  
VD treatment 
Effecacy of  
VD treatment 
Investigation 
 
Adolescents girls  
 
4000 IU, daily for 3 months, than 
2000 IU, daily for 2 months  
Yes Högberg et al., 2012  
 
Young pregnant women 
 
228 IU, daily for pregnancy  Yes Miyake et al., 2017 
 
 
Young postpartum women 
 
1000 IU, daily for 6 months Yes Rouhi et al., 2018 
 
Menopausal women  
with diabetes type 2  
 
50.000 IU, daily for 6 months Yes Penckofer et al., 2017 
 
 
Menopausal women 
 
40.000 IU, per week for 6 months No Kjaergaard et al., 2012 
 
 
Postmenopausal women 
 
20.000/40.000 IU, per week for 1 
year 
Yes Jorde et al., 2008 
 
 
Postmenopausal women 
 
800 IU, daily for 6 months  No Dumville et al., 2006 
 
Postmenopausal women 
 
500.000 IU, per year for 3-5 years Yes Sanders et al., 2011 
 
depression is lacking, although there is some evidence that VD deficiency in development may be relevant to the risk 
of psychosis.  
 In general, several clinical randomized trials are strongly recommended to investigate the interaction between 
repletion of VD stores and affective-related states, especially, depression. Moreover, these trials should contain 
healthy and non-healthy women in different life periods and from different race/ethnicity. While impressive gains 
have been made by researchers to clarify the neurobiology of depression, the contradictory data from clinical and 
preclinical studies underscore that interpersonal as well as non-personal variables may promote to polymorphism of 
depressive disorders, which should be considered as the pathophysiological basis for several different forms of 
treatment . For studying the critical role of VD in depression, research also needs to consider these factors in designing 
any future research with  the aim of treating depression. 
 
LIST OF ABBREVIATIONS 
BDI-II = scale of depressive symptoms  
CES-D = Center for Epidemiologic Studies Depression 
CRH = corticotropin-releasing hormone 
CYP2R1 = 25-hydroxylase 
EPDS = Edinburgh Postnatal Depression Scale  
FSFI = female sexual function  
GC = group component 
HPA = hypothalamic-pituitary-adrenal 
NADSYN1/DHCR7 = 7-dehydrocholesterol reductase  
PHQ-9 = Patient Health Questionnaire 
SF-12 = Short Form 
SNRIs = selective norepinephrine reuptake inhibitors 
SSRIs = selective serotonine reuptake inhibitors 
T2DM = type 2 diabetes mellitus 
VD = Vitamin D 
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